Garrido-Cumbrera, Marco http://orcid.org/0000-0001-9727-1189
Poddubnyy, Denis http://orcid.org/0000-0002-4537-6015
Sommerfleck, Fernando
Bundy, Christine http://orcid.org/0000-0002-5981-3984
Makri, Souzi
Correa-Fernández, José http://orcid.org/0000-0002-7788-5391
Akerkar, Shashank
Lowe, Jo
Karam, Elie http://orcid.org/0000-0002-4681-8225
Navarro-Compán, Victoria http://orcid.org/0000-0002-4527-852X
Funding for this research was provided by:
Novartis Pharma AG
Article History
Received: 15 February 2024
Accepted: 3 April 2024
First Online: 7 June 2024
Declarations
:
: Marco Garrido-Cumbrera: Novartis. Denis Poddubnyy: AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB, AbbVie, MSD, Novartis, Pfizer. Fernando Sommerfleck: Abbvie, Eli Lilly, Janssen, Novartis, Abbvie, Novartis, Janssen. Christine Bundy: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer. Souzi Makri: Novartis, GSK, Bayer. José Correa-Fernández: None declared. Shashank Akerkar: Pfizer, Novartis, Eli Lilly, Jansen. Jo Lowe: No personal funding, but ASIF has received funding from Novartis, UCB, Lilly, Abbvie, Boehringer Ingleheim, Pfizer, Janssen. Elie Karam: None declared. Victoria Navarro-Compán: AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer, UCB Pharma, AbbVie, Eli Lilly, Galapagos, MoonLake, MSD, Novartis, Pfizer, UCB Pharma, AbbVie, Novartis.
: The present manuscript does not contain any studies with animal subjects and the IRB approval was not necessary. All participants were asked to provide explicit opt-in consent prior to participating in the IMAS survey. Furthermore, the participants’ data were anonymized and did not contain confidential, personal or subject-identifying information. Ethical aspects related to data extracted from patients and their treatment were in accordance with the Declaration of Helsinki.